Figure S5 from Removal of Interstitial Hyaluronan Facilitates Subcutaneous Administration and Lymphatic Delivery of Anti-CTLA4 and Improves Antitumor Efficacy

2026 Open access

Read full text
Authors: Gracia Gracia, Enyuan Cao, Daniel Yuen, Vilena D.M. Ferreira, Moore Z. Chen, Danielle Senyschyn, Justine D. Mintern, Angus P. R. Johnston, David W. Kang, Orlagh M. Feeney, Christopher J.H. Porter
DOI: 10.1158/2326-6066.31484153
Cited by: 0

Abstract

Plasma concentrations of αCTLA4 over the 14d treatment period in CT26/HAS tumour mice are similar across dose routes.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Proteoglycans and glycosaminoglycans research Immunotherapy and Immune Responses

Publication details

Publication date
4 March 2026
Language
EN